Avadel Pharmaceuticals — Technical Presentation (April 2020)
24 slides from Avadel Pharmaceuticals's technical presentation, Apr 27, 2020
Slide 1: REST-ON Pivotal Phase 3 Trial: Topline Results
REST - ON Pivotal Phase 3 Trial: Topline Results April 27, 2020
Slide 2: Safe Harbor
Safe Harbor 2 This presentation may include forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 . The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expression
Slide 3: Gregory Divis, Chief Executive Officer
Gregory Divis Chief Executive Officer 3
Slide 4: REST-ON Phase 3 Study – Positive Topline Results
4 REST - ON Phase 3 Study – Positive Topline Results Once - nightly FT218 demonstrated highly statistically significant (p<0.001), clinically meaningful improvement compared to placebo at all three doses for all three co - primary endpoints Once - nightly FT218 was generally well - tolerated at the
Slide 5: Characteristics of Narcolepsy – Serious Disease with Large Unmet Need
Characteristics of Narcolepsy – Serious Disease with Large Unmet Need 5 Under - diagnosed, chronic, disabling neurological disease Characterized by excessive daytime sleepiness (EDS), cataplexy, disrupted nocturnal sleep, hypnagogic hallucinations, and sleep paralysis Twice - nightly sodium oxybate
Slide 6: Leveraging Our Proprietary Micropump Technology – Delivering Sodium Oxybate Once Nightly
Leveraging Our Proprietary Micropump™ Technology – Delivering Sodium Oxybate Once Nightly • Technology contains thousands of micro particles – Each is a miniature delivery system • Microparticulate design can be adapted to each drug’s specific challenges – Modify coatings / thickness Delayed deliver
Slide 7: Initial PK Studies Indicated Potential Advantages of Once-Nightly FT218
0 20 40 60 80 100 0 2 4 6 8 10 Time (h) GHB Concentration (ug/mL) Mean and Standard Error FT218, n=26 Twice - nightly sodium oxybate, n=27 Mean PK Profiles (6 g) Initial Pharmacokinetic (PK) Studies Indicated Potential Advantages of Once - Nightly FT218 The Comparison to 2X Nightly The Results 7 Sin
Slide 8: Jordan Dubow, MD, Chief Medical Officer
Jordan Dubow, MD Chief Medical Officer 8
Slide 9: Positive Topline Phase 3 Results Across All Doses For All Co-Primary Endpoints
Positive Topline Phase 3 Results Across All Doses Studied For All Co - Primary Endpoints 9 Once - Nightly FT218 at 9 g demonstrated a high degree of statistical significance, compared to placebo, for each of the three co - primary endpoints: • Maintenance of Wakefulness Test (MWT) (p<0.001) • Clinic
Slide 10: REST-ON Phase 3 Study Design
3 weeks Baseline REST - ON Phase 3 Study Design 10 Placebo FT218 1 2 3 4 5 6 7 8 9 10 11 12 13 1:1 Randomization 4.5 g 6 g 7.5 g 9 g Weeks safety and efficacy assessments
Slide 11: REST-ON Phase 3 Study – Key Inclusion and Exclusion Criteria
REST - ON Phase 3 Study – Key Inclusion and Exclusion Criteria • Age: 16 and over • Documented diagnosis of narcolepsy (NT1 or NT2) as defined by the International Classification of Sleep Disorders - 3 criteria • Epworth Sleepiness Score (ESS): >10 • May be on stimulants, as long as stable for three
Slide 12: REST-ON Study – Three Co-Primary Endpoints and Statistical Analysis Plan
REST - ON Study – Three Co - Primary Endpoints and Statistical Analysis Plan Change from baseline to endpoint for FT218 compared to placebo at 9 g for: 1. Maintenance of Wakefulness Test 2. Clinical Global Impression - Improvement (% of patients “much” or “very much” improved) 3. Mean weekly cataple
Slide 13: FT218 9 g was Significant on the MWT Compared to Placebo
FT218 9 g was Significant on the MWT Compared to Placebo Change from Baseline to Week 13 for FT218 was 10.82 Change from Baseline to Week 13 for Placebo was 4.69 LS Mean difference between FT218 and Placebo was 6.13 ( p<0.001) Change From Baseline in MWT 4.69 10.82 -1 1 3 5 7 9 11 13 15 Placebo FT21
Slide 14: FT218 9 g Had Significant Improvement on the CGI-I Compared to Placebo
FT218 9 g Had Significant Improvement on the Clinical Global Impression - Improvement (CGI - I) Compared to Placebo 72.0% of patients on FT218 compared to 31.6% of patients on placebo were rated as much or very much improved at Week 13; odds ratio 5.56 (p<0.001) CGI - I - Percent Much or Very Much I
Slide 15: FT218 9 g Had Significant Reduction in Mean Weekly Cataplexy Attacks
FT218 9 g Had Significant Reduction in Mean Weekly Cataplexy Attacks Compared to Placebo 15 Change from Baseline to Week 13 for FT218 was - 11.51 Change from Baseline to Week 13 for Placebo was - 4.86 LS Mean difference between FT218 and Placebo was - 6.65 (p<0.001) Change From Baseline in Weekly Ca
Slide 16: FT218 9 g was Generally Well Tolerated with Low Rates of Adverse Reactions
FT218 (%) Placebo (%) Any Adverse Drug Reaction (ADR) 35.1 5.0 Any Serious ADR 1.3 0.0 ADR Leading To Discontinuation 3.9 0.0 FT218 9 g was Generally Well Tolerated with Low Rates of Commonly Reported Sodium Oxybate Adverse Reactions Common ADRs Nausea 1.3 1.3 Vomiting 5.2 0.0 Decreased Appetite 2.6
Slide 17: FT218 7.5 g and 6 g was Significant on the MWT Compared to Placebo
FT218 7.5 g and 6 g was Significant on the MWT Compared to Placebo 17 Change from Baseline to Week 8 for FT218 7.5 g was 9.55, compared to 3.34 for placebo LS Mean difference between FT218 7.5 g and Placebo was 6.21 (p<0.001) Change from Baseline to Week 3 for FT218 6 g was 8.08, compared to 3.1 for
Slide 18: FT218 7.5 g and 6 g Had Significant Improvements on the CGI-I
18 62.6% of patients on FT218 7.5 g compared to 22.8% of patients on placebo were rated as much or very much improved at Week 8; Odds Ratio 5.67 ( p<0.001) 40.1% of patients on FT218 6 g compared to 6.1% of patients on placebo were rated as much or very much improved at Week 3; Odds Ratio 10.29 (p<0
Slide 19: FT218 7.5 g and 6 g Had Significant Reductions in Mean Weekly Cataplexy Attacks
FT218 7.5 g and 6 g Had Significant Reductions in Mean Weekly Cataplexy Attacks Compared to Placebo 19 Change from Baseline to Week 8 for FT218 7.5 g was - 9.98, compared to - 3.71 LS Mean difference between FT218 7.5 g and Placebo was - 6.27 (p<0.001) Change from Baseline to Week 3 for FT218 6 g wa
Slide 20: Q&A
*Avadel” Q&A
Slide 21: Closing Remarks
\vAvadel” Closing Remarks
Slide 22: What to Expect: Once-Nightly FT218 Next Steps
WHAT TO EXPECT: Once - Nightly FT218 Next Steps Event Status REST - ON completion and topline data Complete Switch and Open Label Extension study In - progress Full REST - ON analysis and complete study report In - progress Pre - NDA meeting In - progress NDA completion and submission In - progress
Slide 23: At a Glance: Once Nightly FT218: All the Ingredients for Success
AT A GLANCE Once Nightly FT218: All the Ingredients for Success 23 FT218 Completed Pivotal Study ~$1.7B a differentiated product with high potential REST - ON Ph3 study, single study required for approval (SPA agreement) 17 YEARS D EMONSTRATED highly significant results across all three co - primary
Slide 24: REST-ON Pivotal Phase 3 Trial: Topline Results
24 REST - ON Pivotal Phase 3 Trial: Topline Results
Avadel Pharmaceuticals — Technical Presentation (April 2020) on 6ix